Certain aminoguanidine compounds, pharmaceutical compositions containing them and their use in treating gastrointestinal motility disorders and disorders associated with cephalic pain

A compound of the formula ##STR27## wherein R.sub.1 hydrogen;

• C.sub.1-6 alkyl;
• (C.sub.1-6 alkyl)carbonyl;
• or benzoyl;
• R.sub.5 is hydrogen;
• halo;
• C.sub.1-6 alkyl;
• hydroxy;
• nitro;
• amino;
• C.sub.1-4 alkylamino;
• C.sub.1-10 alkylcarbonylamino;
• C.sub.2-6 alkoxy-carbonyl;
• SO.sub.2 NR.sub.a R.sub.b ;
• cyano;
• trimethylsilyl;
• C.sub.1-6 alkyl monosubstituted by --SO.sub.2 -(C.sub.1-6 alkyl), --SO.sub.2 NR.sub.a R.sub.b, --CONR.sub.a R.sub.b, --NH--SO.sub.2 --(C.sub.1-6 alkyl), --N (C.sub.1-6 alkyl)--SO.sub.2 --(C.sub.1-6 alkyl), --NR.sub.a R.sub.b, C.sub.2-6 alkoxycarbonyl or --PO(C.sub.1-4 alkyl).sub.2 ;
• carboxy;
• CONR.sub.a R.sub.b ;
• --PO(C.sub.1-4 alkyl).sub.2 ;
• --OCONR.sub.c R.sub.d ;
• C.sub.1-6 alkoxy;
• C.sub.1-6 alkoxy monosubstituted
• by hydroxy, C.sub.1-4 alkoxy, NR.sub.a R'.sub.b, CONR.sub.a R.sub.b, CSNR.sub.a R.sub.b,
• (C.sub.1-6 alkyl)carbonyloxy or benzoyloxy;
• C.sub.2-6 alkenyloxy;
• pyridyl-carbonyloxy;
• (C.sub.1-6 alkyl)carbonyloxy;
• or benzoyloxy;
• and wherever they appear in the above definition of
• R.sub.5, each of R.sub.a and R.sub.b, independently, is hydrogen or C.sub.1-6 alkyl;
• R'.sub.b is hydrogen or C.sub.1-6 alkyl;
• and each of R.sub.c and R.sub.d, independently, is C.sub.1-6 alkyl;
• R.sub.7 is hydrogen, halo, C.sub.1-6 alkyl or C.sub.1-6 alkoxy;
• X--Y is --CR.sub.8 .dbd.N-- or---H(R.sub.8)--NH-- where R.sub.8 is hydrogen or C.sub.1-6 alkyl;
• and
• B is a radical of formula (a) or (b), ##STR28## where n is 1 or 2;
• A.sub.1 is C.dbd.O or CH.sub.2 ;
• X.sub.1 is S;
• NR.sub.11 where R.sub.11 is hydrogen;
• or CR.sub.12 R.sub.13 where each of R.sub.12 and R.sub.13, independently, is hydrogen or C.sub.1-4 alkyl;
• R.sub.10 is hydrogen;
• C.sub.1-12 alkyl;
• C.sub.1-6 alkyl monosubstituted by hydroxy, aryl, aryloxy, adamantyl, a heterocyclic radical, --NH--SO.sub.2 -aryl or --NR.sub.15 --COR.sub.16 where R.sub.15 is hydrogen or C.sub.1-4 alkyl and R.sub.16 is C.sub.1-6 alkyl, C.sub.5-7 cycloalkyl, C.sub.5-7 cycloalkyl-C.sub.1-4 alkyl, aryl or aryl(C.sub.1-4 alkyl);
• C.sub.5-7 cycloalkyl;
• adamantyl;
• (C.sub.1-10 alkyl)-carbonyl;
• benzoyl;
• phenyl(C.sub.1-4 alkyl)carbonyl;
• or --CONHR.sub.14 where R.sub.14 is C.sub.1-10 alkyl or C.sub.5-7 cycloalkyl;
• and wherever "aryl" appears as is or in the significances "aryloxy", "--NH--SO.sub.2 -aryl" or "aryl(C.sub.1-4 alkyl)" in the above definition, it is phenyl or phenyl mono- or disubstituted by fluoro, chloro, methyl or methoxy;
• and wherever the term "a heterocyclic radical" appears in the above definition, it is pyridyl, imidazolyl, benzimidazolyl, pyrrolidinyl, piperidino, pyrazinyl, perhydroindolyl or a radical of formula (d) ##STR29## where E is --CH.sub.2 CH.sub.2 --,--CH.sub.2 N(R.sub.17)-- where R.sub.17 is hydrogen or C.sub.1-4 alkyl;
• or --(CH.sub.2).sub.3 --where one or two hydrogens therein can be replaced by C.sub.1-6 alkyl;
• and E.sub.1 is --CO--or --CH.sub.2 --;
• and
• X.sub.2 is --SR.sub.20 where R.sub.20 is C.sub.1-6 alkyl;
• or --NR.sub.3 R'.sub.10 where either R.sub.3 is hydrogen or C.sub.1-6 alkyl and R'.sub.10 has one of the significances indicated above for R.sub.10 ;
• or R.sub.3 and
• R'.sub.10 together with the nitrogen atom to which they are attached form a heterocyclic radical as defined above;
• with the proviso that where B is a radical of formula (b), only one of R.sub.10 and R'.sub.10 can be other than hydrogen and X.sub.2 can be --SR.sub.20 only when R.sub.10 is hydrogen;
• which compound is in free base or pharmaceutically acceptable salt form.